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Collapsing glomerulopathy: A clinically and pathologically distinct
variant of focal segmental glomerulosclerosis. Sixteen patients with renal
biopsy findings of extensive focal glomerular capillary collapse, visceral
epithelial cell hypertrophy and hyperplasia, and variable degrees of
tubulointerstitial injury in the absence of evidence for human immuno-
deficiency virus (HIV) infection or intravenous drug abuse were pro-
spectively identified by renal biopsy. The pathologic process was
designated collapsing glomerulopathy to distinguish it from other pat-
terns of focal glomerular sclerosis. The clinical and pathologic charac-
teristics of these 16 patients were analyzed and compared to a group of
25 patients with noncollapsing focal segmental glomerulosclerosis
(FSGS). Thirteen of 16 patients with collapsing glomerulopathy were
black as compared with 11 of 25 with FSGS (P = 0.018). The most
common findings at presentation were hypertension and manifestations
of the nephrotic syndrome. Although the duration of symptoms prior to
presentation was no longer in the collapsing glomerulopathy group, the
presenting mean serum creatinine was higher in patients with collapsing
glomerulopathy than in those with noncollapsing FSGS (3.5 3.4 mgldl
vs. 1.3 0.6 mg/dl, P = 0.001). Twenty-four-hour urine protein excretion
was also higher in the collapsing glomerulopathy group (13.2 7.7
g/day vs. 4.6 4.5 g/day FSGS, P = 0.005). The collapsing glomerul-
opathy patients had a mean age of 41.4 19.1 (range 19 to 81), a
male-to-female ratio of 11:5 and a black-to-white ratio of 13:3. Renal
survival, evaluated by life-table analysis, was markedly worse in
collapsing glomerulopathy patients than in FSGS patients (P = 0.0004).
It is proposed that collapsing glomerulopathy is a distinct entity
characterized by black racial predominance, massive proteinuria, rela-
tively rapidly progressive renal insufficiency, and distinctive pathologic
findings. The data suggest that collapsing glomerulopathy is clinically,
pathologically, and epidemiologically different from noncollapsing
FSGS. Although collapsing glomerulopathy resembles HIV-nephropa-
thy both pathologically and clinically, it differs clinically by having no
evidence for associated HIV infection and differs pathologically by
lacking endothelial tubuloreticular inclusions,
In 1986 Weiss et al reported six patients with nephrotic
syndrome, progressive irreversible renal failure, and predomi-
nant pathologic features of glomerular capillary collapse and
visceral epithelial cell swelling and hyperplasia [11. They sug-
gested that this may be a distinct clinicopathologic entity.
Similar glomerular findings have been reported in patients with
human immunodeficiency virus (HIV) infection, where the
lesion is often referred to as HIV-nephropathy [2]. With the
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exception of one patient reported to have developed AIDS,
HIV status was not addressed in the patients described by
Weiss Ct al [1]. This omission has led to speculation that the
patients described by Weiss Ct al may actually have had
unrecognized HIV-nephropathy [3].
We have prospectively identified 16 patients, without evi-
dence of HIV infection or known HIV risk factors, who
exhibited pathologic features similar to those described by
Weiss et al [1]. We have designated this lesion collapsing
glomerulopathy. The epidemiologic, clinical, pathologic, and
prognostic characteristics of these 16 patients are described and
compared to a group of patients with classic primary focal
segmental glomeruloscierosis.
Methods
Patient selection
Out of 849 consecutive nontransplant renal biopsies evalu-
ated at the University of North Carolina between November
1988 and October 1990, 16 specimens with pathologic features
of collapsing glomerulopathy and no evidence for HIV infection
or intravenous drug abuse were prospectively identified. Biopsy
diagnosis of collapsing glomerulopathy was based on light
microscopic findings of focal segmental or global glomerular
capillary collapse, wrinkling and folding of the basement mem-
branes within the collapsed segments, and visceral epithelial
cell hypertrophy and hyperplasia, sometimes accompanied by
conspicuous cytoplasmic hyaline droplets. Other associated
pathologic features, such as mesangial matrix expansion, scle-
rosis, and tubulointerstitial injury were noted but were not
utilized as primary criteria for diagnosis. Exclusion criteria
included HIV seropositivity, history of intravenous drug abuse,
and any evidence of other HIV risk factors. Through the
Glomerular Disease Collaborative Network (GDCN), which is a
collaborating group of over 120 nephrologists, clinical data on
all 16 patients were obtained. Follow-up data were obtained
until the completion of the study in May 1992. Study end-points
were defined as end-stage renal disease or death caused by
complications of renal failure.
Without knowledge of their clinical status, 25 patients with a
renal biopsy diagnosis of noncollapsing FSGS were randomly
selected as a comparison group. Patients with glomerular tip
lesion were classified separately and were not included in the
comparison group [41. Presenting clinical data and follow-up
Detwiler et a!: Collapsing glomerulopathy 1417
Fig. 1. Collapsing glomerulopathy (A) and
noncollapsing FSGS (B). Note the epithelial
hypertrophy and hyperplasia in A and the
perihilar location of the segmental sclerosis in
B. Periodic acid Schiff stain (magnification A,
225x and B, 150x).
data were obtained through the GDCN in a fashion similar to
the study group.
Pathology analysis
All collapsing glomerulopathy and FSGS biopsy specimens
were evaluated by light microscopy using standard paraffin
section techniques. Eleven to 13 levels of section were stained
with hematoxylin and eosin, periodic acid-Schiff (PAS), Mas-
son trichrome, or combined hematoxylin and eosin and methe-
namine silver technique. There were an average of 17 glomeruli
per level of section in the collapsing glomerulopathy specimens,
and 20 per level of section in the FSGS specimens. At the time
of initial renal biopsy evaluation, a diagnosis of collapsing
glomerulopathy was made if a majority of injured glomeruli
(excluding those with global end-stage sclerosis, that is, total
obsolescence) had segmental or global capillary collapse asso-
ciated with epithelial hypertrophy. Epithelial hyaline droplets
and hyperplasia were typically present, but were not required
for diagnosis. If there was clinical evidence for HIV infection or
intravenous drug abuse at the time of biopsy, the patients were
excluded from the cohort of collapsing glomerulopathy patients
evaluated in this study. A diagnosis of glomerular tip lesion was
made if there was focal glomerular consolidation, cellular
swelling, foam cell formation and sclerosis confined exclusively
to the glomerular tip opposite the hilum. A diagnosis of FSGS
was made if: (1) the criteria for neither of these diagnoses were
present; (2) there was focal segmental glomerular sclerosis; and
(3) there was no pathologic evidence for primary disease that
could have produced secondary sclerosis, such as ultrastruc-
tural evidence for basement membrane nephropathy or immu-
nohistologic evidence for immune complex mediated glomeru-
lonephntis. All collapsing glomerulopathy specimens [16] were
selected for evaluation. A comparison group of 25 noncollaps-
ing FSGS specimens were randomly selected from patients with
a pathologic diagnosis of FSGS.
Fifteen collapsing glomerulopathy specimens were evaluated
by direct immunofluorescence microscopy after staining with
antibodies specific for IgG, IgA, 1gM, lambda light chains,
kappa light chains, C3, Clq and fibrin. All 16 collapsing
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Fig. 2. Focal global glomerular collapse with
marked visceral epithelial hypertrophy. Note
also the interstitial infiltration of mononuclear
leukocytes. Methenamine silver stain
(magnification 170X).
Fig. 3. Light microscopy of one glomerulus
with capillary collapse and hypertrophy of
visceral epithelial cells, many of which
contain droplets. Methenamine silver stain
(magnification 400x).
glomerulopathy specimens were evaluated by standard trans-
mission electron microscopy. The 25 FSGS specimens that
were compared to the collapsing glomerulopathy specimens
were similarly evaluated by immunofluorescence and electron
microscopy.
Statistical analysis
Differences in laboratory values between the collapsing glom-
erulopathy and FSGS groups were tested using Wilcoxon's
rank sum test. Comparisons of race and gender between groups
were made using a continuity adjusted Chi-square test. Bonfer-
roni inequality was used for adjusting the P-values to account
for multiple testing. Wilcoxon and likelihood ratio tests for
survival curves were used to compute non-parametric estimates
to test for equality of survival curves between the two groups.
The log rank test was used to test for association of survival
time with covariates. A parametric model for time failure data
was fit in order to test the significance of diagnosis (collapsing
glomerulopathy versus FSGS) while adjusting for the presence
of other effects, Reciprocal creatinine was used to provide a
Gaussian distribution of this variable for the model [5].
Results
Renal biopsy findings
The pathologic sine qua non for a diagnosis of collapsing
glomerulopathy was the presence of focal, segmental or global
glomerular capillary collapse (Figs. 1 through 4). This lesion
was characterized by collapse and wrinkling of glomerulai
basement membranes, obliteration of capillary lumens, disap.
pearance of endothelial and mesangial cells, and hypertrophy
and hyperplasia of adjacent visceral epithelial cells. Table I
demonstrates the percentage of glomeruli in each specimen
involved by collapsing lesions, as well as the percentage ol
glomeruli with end-stage sclerosis and the severity of glomeru-
lar epithelial alterations and tubulointerstitial injury. When the
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Fig. 4. PAS.positive hyaline droplets in hypertrophied visceral epithe-
ha! cells. Periodic acid-Schiff stain (magnification 500x).
Table 1. Severity of injury in renal biopsies from patients with
collapsing glomerulopathy
Patient
Active
collapsing s
lesionsa
Chronic
clerosing
lesions"
Glomerular
epithelial
hypertrophyc
Glomerular
epithelial
dropletse
Tubulointerstial
injuryc
1 92 0 3 3 3
2 69 0 2 3 3
3 63 0 4 3 3
4 63 0 3 3 2
5 56 0 2 1 3
6 55 0 3 2 2
7 50 0 2 0 1
8 38 31 4 2 4
9 35 20 1 1 1
10 33 8 1 0 2
11 20 0 2 1 2
12 17 0 2 3 2
13 17 17 2 3 4
14 13 13 1 1 2
15 11 56 1 1 3
16 8 38 1 1 3
order of decreasing frequency of activePatients are arranged in
collapsing lesions.
a Percent of glomeruli with segmental or global collapse and epithelial
changes, but without end-stage global sclerosis
Percent of glomeruli with global end-stage sclerosis
Severity on a scale of 0 to 4+ with 0 = none and 4+ = severe
injury was segmental, there was no predilection for the perihilar
or tip segments. This differed from the lesions in noncollapsing
FSGS, which had a predilection for perihilar segments (Fig.
1B). The noncollapsing FSGS lesions also had more hyalinosis.
Extrapolating from the least severe to the most severe
lesions, it appeared that the earliest change was hypertrophy of
epithelial cells and capillary collapse, followed by loss of
endothelial and mesangial cells, and finally increase in amor-
phous matrix material. The end-stage glomerular lesion of
collapsing glomerulopathy appeared to be dense global sclerosis
that was indistinguishable from end stage sclerosis caused by
other types of glomerular injury. Table 1 demonstrates that the
specimens with the greatest amount of active glomerular col-
lapse (that is, collapse with adjacent epithelial changes) had the
least end-stage global sclerosis.
Silver and periodic acid-Schiff stains were most effective in
demonstrating the basement membrane and matrix lesions.
Compared to noncollapsing FSGS and the sclerosing phase of
inflammatory glomerulonephntides, the injured segments in
collapsing glomerulopathy had much less tendency to form
adhesions to Bowman's capsule, although a few adhesions did
occur. Hypertrophied epithelial cells sometimes contained large
hyaline droplets that were intensely periodic acid-Schiff posi-
tive and fuchsinophilic, and variably silver-positive (Figs. 3 and
4). Hypertrophied epithelial cells often had large nuclei, some-
times with large nucleoli. In a few glomeruli, the epithelial
hypertrophy and hyperplasia was so marked that it resembled
crescent formation; however, close inspection revealed in-
crease in epithelial mass predominantly as a result of cell
enlargement rather than cell proliferation and involvement of
primarily the visceral rather than the parietal epithelial cells.
All 16 specimens had some degree of focal interstitial fibrosis,
tubular atrophy and interstitial influx of predominantly mono-
nuclear leukocytes. Foci of dilated tubules containing amor-
phous cast material often were present. In most specimens,
proximal tubular epithelial cells had conspicuous resorption
droplets. In occasional specimens, some proximal tubular epi-
thelial cells contained massive numbers of large resorption
droplets while others had no droplets. Fourteen specimens had
sclerotic changes in arteries and arterioles, which ranged from
mild to marked.
By immunofluorescence microscopy, the injured glomerular
segments usually had irregular staining for 1gM, C3 and Clq
(Fig, 5). Of the 15 specimens evaluated, five had segmental to
global mesangial staining for C3, 3 mesangial staining for C3,
and 3 mesangial staining for Clq. Hypertrophied visceral epi-
thelial cells sometimes contained resorption droplets that
stained with antibodies against immunoglobulins and comple-
ment (Fig. 5). Otherwise, there was no significant staining of
glomeruli with antibodies specific for IgG, IgA or fibrin.
By electron microscopy, there was variable effacement of
visceral epithelial cell foot processes and microvillous transfor-
mation of epithelial cytoplasm. Some visceral epithelial cells
had markedly increased cytoplasm that contained clear or
electron dense vacuoles. Some epithelial cells had reticulogran-
ular changes in nuclear chromatin and a few intranuclear
inclusions. There were no capillary wall or mesangial immune
complex-type electron dense deposits. Only one of the 16
specimens had endothelial tubuloreticular inclusions, and in
this specimen they were sparse.
Clinical characteristics
Mean age at diagnosis was 41.4 19.1 years (range 19 to 81)
for the collapsing glomerulopathy patients and 35.4 11.7
years (range 15 to 54) in the FSGS patients (P = NS). Male sex
was predominant in both groups (male:female ratio 11:5 for
collapsing glomerulopathy vs. 14:11 for FSGS, P = NS). Black
race was disproportionately represented in the collapsing gb-
merulopathy group compared with the FSGS group (13 of 16 vs.
11 of 25 black, P = 0.018). This black:white ratio of 13:3 was
— SS. t.
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dramatically higher than the overall ratio of 1:2 in our renal
biopsy population.
Duration of symptoms prior to presentation was less than six
months in all collapsing glomerulopathy patients, with the
exception of one patient with proteinuria and a biopsy diagnosis
of minimal change glomerulopathy made three years prior to
diagnosis of collapsing glomerulopathy. The most common
presenting clinical findings in collapsing glomerulopathy pa-
tients were hypertension and manifestations of the nephrotic
syndrome. Many patients also experienced fevers, anorexia,
weight loss, and diarrhea (Tables 2 and 3). The presence of
hypertension was not significantly different between the col-
lapsing glomerulopathy and FSGS groups. Prior documented
illnesses included five patients with a history of "essential"
hypertension, two patients with coronary artery disease, and
one patient each with morbid obesity, rheumatoid arthritis,
asthma, chronic urticaria, psoriasis, minimal change glomerul-
opathy, and childhood "Bright's disease." Two patients devel-
oped a debilitating illness characterized by diffuse muscle
weakness and dementia of unknown cause. Seven patients had
a recent history of non-steroidal anti-inflammatory drug inges-
tion. No patients had known toxin exposure. All 12 patients
tested serologically for HIV infection and all nine tested for
hepatitis B infection were negative. The patients untested for
HIV and/or hepatitis B had no evidence for acquired immuno-
deficiency syndrome (AIDS) or hepatitis at the time of biopsy or
after follow-up, and denied all risk factors for obtaining these
viruses. One patient had a family history of renal disease in
multiple family members, although pathologic confirmation of
the renal disease in the relatives was not available.
Presenting serum creatinine was significantly higher in the
collapsing glomerulopathy patients than the FSGS patients (3.5
3.4mg/dl vs. 1.3 0.6mgldl, P = 0.001). Ten of 16 collapsing
glomerulopathy patients had entry serum creatinine >2.0 mgldl
whereas only two of 25 FSGS patients had serum creatinine
>2.0 mg/dl (Fig. 6). Twenty-four-hour urinary protein excretion
was significantly higher in the collapsing glomerulopathy pa-
tients than those with FSGS (13.2 7.7 g/day vs. 4.6 4.5 g/day,
P = 0.005). Eleven of 15 patients with collapsing glomerulopa-
thy had >10 g/day urine protein excretion, whereas only one of
Hypertension 56%
Peripheral edema 56%
Anorexia/weight loss 44%
Fever (subjective) 25%
Dyspnea 25%
Diarrhea 19%
Ascites 19%
Pleural effusion 19%
Dementia 13%
Arthralgias/myalgias 13%
Rash 13%
Polyuria 6%
Hypercholesterolemia 100%
Hypoalbuminemia 88%
Nephrotic range proteinuria (>3.5 g/day) 81%
Pyuria 58%
Anemia 29%
Microscopic hematuria 27%
Leukocytosis 21%
Hyponatremia 7%
Hypokalemia 7%
Eosinophilia 7%
25 FSGS patients had >10 glday (Fig. 7). Serum albumin was
lower in the collapsing glomerulopathy group, although this was
not statistically significant (2.4 0.9 vs. 3.4 1.0 mg/dI, P =
NS). Total cholesterol was not statistically significantly differ-
ent between the two groups (368 174 collapsing glomerulopathy
vs. 262 109 FSGS, P = NS).
Two collapsing glomerulopathy patients had anti-nuclear
antibody positivity at a titer of 1:80. No patients were noted to
have gross hematuria, dysuria, thrombocytopenia, thrombocy-
tosis, leukopenia, transaminase elevation, hypocomplement-
emia, coagulopathy, hyperkalemia, hyperglycemia, or hyperna-
tremia. There was no significant difference between the two
groups with regard to hematocrit.
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Fig. 5. Direct immunofluorescence
microscopy demonstrating irregular segmental
glomerular immunostaining corresponding to
a collapsed segment, as well as staining of
droplets within visceral epithelial cells. Anti-
C3 (magnification 400x).
Table 2. Presenting clinical features of patients with collapsing
glomerulopathy (N = 16)
Table 3. Laboratory findings at presentation in patients with
collapsing glomerulopathy (N = 16)
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CO FSGS
Fig. 6. Serum creatinine at presentation. Individual entry serum cre-
atinine in mg/dl for collapsing glomerulopathy (CG) and FSGS patients.
Note that 10 of 16 CC patients had entry creatinine >2.0 mg/dl while
only 2 of 25 FSGS patients were >2.0 mg/dl. Mean values SD for CO
and FSGS were 3.5 3.4 and 1.3 0.6 mgldl, respectively (P = 0.001).
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Fig. 7. Urinary protein excretion at presentation. Individual 24-hour
urinary protein excretion in g124 hr for collapsing glomerulopathy (CG)
and FSGS patients. Note that 11 of 15 CC patients had >10 g/24 hours
while only 2 of 25 with FSGS exceeded 10 g124 hours. Mean values
SD were 13.2 7.7 and 4.6 4.5 for CO and FSGS patients,
respectively (P = 0.005).
(20) (18) (15)
0 3 6 9 12 15 18 21
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Fig. 8. Renal survival. Life-table analysis of patients with collapsing
glomerulopathy (- - -; N =16; P = 0.0004) vs. FSGS (—; N = 25).
End-points for renal survival were defined as end-stage renal disease or
death due to renal failure. The number of patients at 6, 12, 18, and 21
months with available follow-up who had not reached a study end-point
is shown in parentheses.
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Renal survival and treatment
Adequate follow-up data were available on 14 of 16 patients
with collapsing glomerulopathy and 22 of 25 with FSGS. Renal
survival, as determined by life-table analysis, was significantly
worse in the collapsing glomerulopathy patients (Fig. 8, P =
0.0004). This poor outcome correlated with the type of injury
irrespective of entry serum creatinine or race. In other words,
the difference in survival between FSGS and collapsing glom-
erulopathy remained statistically significant when controlling
for entry serum creatinine and race (P = 0.0028).
Of the 14 collapsing glomerulopathy patients with follow-up
data, within 15 months, five were on dialysis and three had died
of complications of renal failure. By comparison, during the
first 15-months of follow-up, none of the FSGS patients was on
dialysis and none had died. Of the six patients with collapsing
glomerulopathy not reaching a study end-point, one had an
apparent clinical remission, four had persistent nephrotic syn-
drome, and one patient presenting with asymptomatic non-
nephrotic proteinuria remained asymptomatic. The three
patients who died with collapsing glomerulopathy had unwit-
nessed cardiopulmonary arrests with anasarca and renal insuf-
ficiency (Cr> 2.0 mg/dl) documented just prior to death. One of
these patients had fever and oliguna prior to death, one was
awaiting permanent access placement for dialysis, and one died
at home with severe malnutrition and fluid overload after
multiple hospitalizations for treatment of infections and fluid
management.
Five of 14 patients with collapsing glomerulopathy and avail-
able follow-up data were treated with immunosuppressive ther-
apy. Of four patients treated with corticosteroids alone, one
died, two had persistent nephrotic syndrome, and one experi-
enced clinical remission. One patient was treated with cyclo-
phosphamide and corticosteroids with no reduction in protein-
uria and progression of renal insufficiency.
Discussion
Weiss et al originally described a disease with the unusual
renal histopathologic findings of prominent glomerular capillary
collapse, visceral epithelial cell swelling with hyaline droplets,
and extensive tubulointerstitial inflammation combined with an
aggressive clinical course of progressive renal insufficiency and
nephrotic syndrome [1]. There have been no further confirma-
tory studies supporting the claim that this disease might be a
distinct clinicopathologic entity. In fact, the possibility has been
raised that the patients reported by Weiss et al may have had
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HIV infection, and therefore that the observed disease might
have been unrecognized HIV-nephropathy [3]. We have, how-
ever, identified 16 patients with pathologic findings identical to
those described by Weiss et al who have no evidence for AIDS
or HIV infection.
Clinical characteristics of these patients with collapsing glom-
erulopathy included strong black racial predilection, a wide age
distribution, slight male predominance, massive proteinuria
with nephrotic syndrome, high likelihood of baseline renal
insufficiency, and poor renal survival. The somewhat overlap-
ping histologic features of the focal lesions of collapsing glom-
erulopathy with those of noncollapsing FSGS raises the possi-
bility that this lesion has been classified as FSGS by other
pathologists. However, in the current study, comparison of
collapsing glomerulopathy patients to patients with noncollaps-
ing FSGS revealed striking epidemiologic, clinical and patho-
logic differences. Patients with collapsing glomerulopathy are
more likely to be black, are more prone to have >10 glday
proteinuria, have a higher likelihood of baseline renal insuffi-
ciency, and progress to end-stage renal disease or death caused
by renal failure much more rapidly than those with FSGS.
Pathologically, collapsing glomerulopathy differs from noncol-
lapsing FSGS in that there are: (I) extensive and often global
collapse of the glomerular tufts without as much matrix expan-
sion or adhesion formation as is usual for FSGS; (2) striking
visceral epithelial cell hypertrophy, usually accompanied by
conspicuous cytoplasmic hyaline droplets; (3) no predilection
for perihilar segment; and (4) more extensive tubulointerstitial
inflammation, tubular atrophy and fibrosis than in FSGS with a
comparable degree of glomerular injury.
Other investigators have suggested that advanced tubuloin-
terstitial injury [6], presence of visceral epithelial cell changes
[7], and large amounts of proteinuna [8, 9] are poor prognostic
indicators in FSGS. It is possible that some of these reports
included patients we have classified in this study as collapsing
glomerulopathy.
Collapsing glomerulopathy does not appear merely to repre-
sent an advanced form of FSGS. This is supported by the
relatively short duration of symptoms in collapsing glomerul-
opathy patients prior to presentation, the known natural patho-
logic progression of FSGS [10], which does not pass through a
late phase that resembles collapsing glomerulopathy, and the
observation that patients in the comparison FSGS group did not
develop a similar clinical course even after an extended fol-
low-up period.
Additional support for collapsing glomerulopathy being dis-
tinct from FSGS is provided by a preliminary report from
Szabolcs and associates [11]. Using immunohistochemical
markers for cell proliferation, they observed that, compared to
noncollapsing FSGS, collapsing glomerulopathy had an in-
creased expression of proliferation markers in glomerular and
tubular epithelial cells.
We have been intrigued by the pathologic and clinical simi-
larities between collapsing glomerulopathy and HIV-nephropa-
thy. Early reports of renal disease in AIDS described FSGS in
addition to other lesions [12—14]. The focal glomerular sclerosis
of HIV-nephropathy was initially felt to be indistinguishable
from other forms of FSGS [12]. However, careful analysis has
revealed histopathologic and ultrastructural features that differ-
entiate HIV-nephropathy from FSGS [2, 15, 16]. D'Agati et al
recently described the characteristic glomerular lesion of HIV
nephropathy as "global, prominent 'collapse' of the glomerular
tuft . . . defined as a severe retraction of the glomerular capil-
lary walls with resulting loss of patency of glomerular capillary
lumens, but without increase in mesangial matrix or intracapil-
lary matrix" [2]. They also emphasized, as have other authors,
the prominent tubulointerstitial changes and visceral epithelial
cell hypertrophy of HIV-nephropathy [2,15,16]. This pathologic
description closely approximates what we have observed in
collapsing glomerulopathy. Clinically, the course of collapsing
glomerulopathy and HIV-nephropathy are similar in that both
are characterized by rapidly progressive renal failure and
severe proteinuria [17, 18].
In view of these striking clinical and pathologic similarities,
we have carefully attempted to eliminate the possibility that
collapsing glomerulopathy actually is unrecognized HIV-
nephropathy. HIV seronegativity was demonstrated in all 12
patients who could be tested. We also carefully reviewed the
social history of the study patients with particular attention to
any history of HIV risk factors, including a history of intrave-
nous drug abuse. Furthermore, although HIV-nephropathy and
collapsing glomerulopathy are similar pathologically, there was
an important difference, namely the absence of endothelial
tubuloreticular inclusions in 15 of 16 collapsing glomerulopathy
biopsies (the one patient with tubuloreticular inclusions also
had a positive antinuclear antibody assay but no glomerular
immune complex deposits). In our experience, and in published
reports [15, 16], endothelial tubuloreticular inclusions are
present in 80% to 90% of specimens with HIV-nephropathy
compared to approximately 10% of all renal biopsy specimens.
Finally, no patient developed clinical evidence of AIDS during
the follow-up period.
Although the collapsing glomerulopathy patients do not have
evidence to suggest HIV as a cofactor for their renal disease,
the possibility that HIV-nephropathy and collapsing glomerul-
opathy are pathophysiologically related cannot be excluded. An
infection, other than HIV, common to patients with HIV-
nephropathy and collapsing glomerulopathy could be causing
both diseases, and might explain the systemic symptoms expe-
rienced by some of the collapsing glomerulopathy patients.
However, because there is evidence from animal and human
studies that HIV may be directly responsible for the injury in
HIV-nephropathy [19, 20], any theory attempting to link HIV
nephropathy and collapsing glomerulopathy would imply a
common response to different, although possibly related, etio-
logic stimuli. In support of a possible viral etiology are data
indicating that viruses other than HIV can cause focal scleros-
ing glomerular injury. Mice transgenic for recombinant retrovi-
rus MPSVneo [21] and the early portion of Simian virus 40 [22]
have both been demonstrated to develop focal glomerular
sclerosis. In humans, focal glomerular sclerosis was reported in
a patient with HIV II infection, although it is unclear from the
pathologic description if this was a lesion similar to collapsing
glomerulopathy [23]. Therefore, a retroviral infection other
than HIV is an attractive but highly speculative hypothesis for
the etiology of collapsing glomerulopathy.
Intravenous drug abuse may be a cofactor in the development
of HIV nephropathy [24]. It is also associated with FSGS in the
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absence of HIV infection [25, 26]. Intravenous drug abuse-
induced FSGS is reported to be pathologically similar to idio-
pathic FSGS, although like collapsing glomerulopathy and
HIV-nephropathy it carries a worse prognosis [25, 26]. We have
observed several patients with a history of intravenous drug
abuse and no evidence for HIV infection who have had patho-
logic findings similar to those of collapsing glomerulopathy.
Because of the link between intravenous drug abuse and HIV
infection, as well as the link with focal glomerular sclerosis, all
patients with a history of intravenous drug abuse were excluded
from the current study. We also excluded patients with renal
transplants from this study, although we have seen de novo or
recurrent collapsing glomerulopathy in four renal allografts.
The failure to detect hepatitis B seropositivity in our patients
with collapsing glomerulopathy lends further support to the
contention that we were able to exclude intravenous drug abuse
as a potential contributor to the observed glomerular injury. It
seems unlikely that intravenous drug abuse is linked to the
pathogenesis of the collapsing glomerulopathy in the 16 patients
reported here. However, our unpublished observation that a
collapsing glomerulopathy pattern of injury does occur in
patients with intravenous drug abuse suggests that collapsing
glomerulopathy may occur in this population.
The history of proteinuria in relatives of two patients with
collapsing glomerulopathy and the striking black racial predi-
lection suggest a possible genetic component to this disorder.
Black race also has been considered a risk factor in HIV-
nephropathy [17, 24, 27] and intravenous drug abuse nephrop-
athy [28]. It is conceivable that there is a genetic predisposition
to development of the pattern of glomerular collapse and injury
observed in collapsing glomerulopathy, HIV infection, and
intravenous drug abuse [27]. Alternatively, these three groups
could share some other etiologic factor; for example, exposure
and susceptibility to an infectious pathogen capable of causing
this pattern of glomerular injury.
The prevalence and geographic distribution of collapsing
glomerulopathy remain to be determined. During the interval in
which patients were being entered into this study, November
1988 and October 1990, 1.9% of renal biopsy specimens evalu-
ated by the University of North Carolina Nephropathology
Laboratory had collapsing glomerulopathy. It is our impression
that this pattern of disease was rare in our region until recently,
and is now increasing in frequency. Recently, Valeri and
associates have reported an increasing frequency of collapsing
glomerulopathy in New York [29]. As is true in our patients, the
disease in their patients, compared to FSGS, was characterized
by greater black racial predominance, more severe nephrosis,
more marked visceral epithelial and tubulointerstitial lesions,
and more rapid progression to end-stage renal disease. Also of
interest is a report from Zaire noting a striking increase in FSGS
in the recent past [30]. The photomicrographs in this publication
raise the possibility that the disease that is increasing in
frequency in Zaire is collapsing glomerulopathy. In fact, in the
legend to their Figure 4 they note that "epithelial hyperplasia
coexists with collapsed sclerotic areas" in the glomeruli [30]. A
problem with drawing conclusions from these data, however, is
the lack of systematic data on testing for HIV infection.
In conclusion, collapsing glomerulopathy is characterized by
black racial predominance, massive proteinuria, and, in a high
proportion of patients, relatively rapid progression to end-stage
renal disease. Its predominant histopathologic findings are focal
glomerular capillary collapse, visceral epithelial cell hypertro-
phy, hyperplasia and hyaline droplet formation, and associated
tubulointerstitial injury. Focal glomerular injury with the patho-
logic features of collapsing glomerulopathy causes more severe
nephrosis and renal insufficiency at presentation, and more
rapid progression of renal failure than glomerular sclerosis
without collapsing features. Although collapsing glomerulopa-
thy is clinically and pathologically similar to HIV nephropathy,
it occurs in patients without evidence of HIV infection and
pathologically lacks endothelial tubuloreticular inclusions. Col-
lapsing glomerulopathy is clinically, pathologically, and epide-
miologically distinct from noncollapsing FSGS, but the pres-
ence of variable degrees of focal glomerular sclerosis raises the
possibility that it may ultimately be classified as an aggressive
or malignant subcategory of FSGS.
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